Abstract:Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients' quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold. If symptoms persist despite this adjustment, the next step involves the use of omalizumab, a monoclonal anti-IgE antibody, which has shown efficacy in the majority of cases. However, a subset of patients remains refractory, necessitating alternative treatments such as immunosuppressive agents like cyclosporine or azathioprine. To address these unmet needs, several new therapeutic targets are being explored. Among them, significant attention is being given to drugs that block Bruton's tyrosine kinase (BTK), such as remibrutinib, which reduces mast cell activation. Therapies like dupilumab, which target the interleukin-4 (IL-4) and IL-13 pathways, are also under investigation. Additionally, molecules targeting the Mas-related G protein-coupled receptor X2 (MRGPRX2), and those inhibiting the tyrosine kinase receptor Kit, such as barzolvolimab, show promise in clinical studies. These emerging treatments offer new options for patients with difficult-to-treat CSU and have the potential to modify the natural course of the disease by targeting key immune pathways, helping to achieve longer-term remission. Further research is essential to better elucidate the pathophysiology of CSU and optimize treatment protocols to achieve long-term benefits in managing this condition. Altogether, the future of CSU treatments that target pathogenetic mechanisms seems promising.

Immunopathogenesis of urticaria: a clinical perspective on histamine and cytokine involvement

[Urticaria. New developments and perspectives]

Advanced Biomarkers: Therapeutic and Diagnostic Targets in Urticaria

Update on Histamine and Antihistamines

Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment

Genetic Variants Leading to Urticaria and Angioedema and Associated Biomarkers

Research progress in the pathogenesis of chronic urticaria.

Prevalence and phenotypic features of chronic spontaneous urticaria

The Role of Crosstalk of Immune Cells in Pathogenesis of Chronic Spontaneous Urticaria

Autoimmune Theories of Chronic Spontaneous Urticaria

Neuro-Immuno-Psychological Aspects of Chronic Urticaria

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management

The role and relevance of mast cells in urticaria

Pathophysiological Mechanisms of the Onset, Development, and Disappearance Phases of Skin Eruptions in Chronic Spontaneous Urticaria

Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances

Heat urticaria: a revision of published cases with an update on classification and management

Biomarkers of Autoimmune Chronic Spontaneous Urticaria

Mast cell signaling and its role in urticaria

Research hotspots in urticaria: A bibliometric study of the top 100 most cited articles

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments